S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in

CRISPR Therapeutics Stock Forecast, Price & News

-1.59 (-1.25 %)
(As of 02/26/2021 12:00 AM ET)
Today's Range
Now: $125.69
50-Day Range
MA: $171.54
52-Week Range
Now: $125.69
Volume2.48 million shs
Average Volume2.49 million shs
Market Capitalization$9.48 billion
P/E RatioN/A
Dividend YieldN/A
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
CRISPR Therapeutics logo


CRISPR Therapeutics: Roadblock Ahead
February 25, 2021 |  seekingalpha.com
Bear of the Day: CRISPR Therapeutics (CRSP)
February 11, 2021 |  finance.yahoo.com
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
February 5, 2021 |  finance.yahoo.com
CRSP Feb 2021 155.000 call
February 2, 2021 |  au.finance.yahoo.com
CRSP Jul 2021 75.000 put
February 2, 2021 |  au.finance.yahoo.com
CRSP Jan 2022 310.000 call
January 23, 2021 |  uk.finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:CRSP
Year FoundedN/A



Sales & Book Value

Annual Sales$289.59 million
Cash Flow$0.82 per share
Book Value$17.02 per share


Net Income$66.86 million
Net Margins-273.10%


Market Cap$9.48 billion
Next Earnings Date4/27/2021 (Estimated)


Overall MarketRank

1.53 out of 5 stars

Medical Sector

426th out of 1,956 stocks

Biological Products, Except Diagnostic Industry

57th out of 177 stocks

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
-1.59 (-1.25 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRSP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

CRISPR Therapeutics (NASDAQ:CRSP) Frequently Asked Questions

Is CRISPR Therapeutics a buy right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRISPR Therapeutics stock.
View analyst ratings for CRISPR Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than CRISPR Therapeutics?

Wall Street analysts have given CRISPR Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CRISPR Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting CRISPR Therapeutics?

CRISPR Therapeutics saw a drop in short interest in the month of January. As of January 29th, there was short interest totaling 2,950,000 shares, a drop of 19.0% from the January 14th total of 3,640,000 shares. Based on an average daily trading volume, of 1,920,000 shares, the days-to-cover ratio is presently 1.5 days.
View CRISPR Therapeutics' Short Interest

When is CRISPR Therapeutics' next earnings date?

CRISPR Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, April 27th 2021.
View our earnings forecast for CRISPR Therapeutics

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) announced its quarterly earnings data on Monday, February, 15th. The company reported ($1.50) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.27) by $0.23. The business had revenue of $0.37 million for the quarter, compared to analyst estimates of $4.69 million. CRISPR Therapeutics had a negative trailing twelve-month return on equity of 20.72% and a negative net margin of 273.10%.
View CRISPR Therapeutics' earnings history

How has CRISPR Therapeutics' stock been impacted by Coronavirus (COVID-19)?

CRISPR Therapeutics' stock was trading at $43.28 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CRSP shares have increased by 190.4% and is now trading at $125.69.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CRSP?

17 brokers have issued twelve-month price targets for CRISPR Therapeutics' stock. Their forecasts range from $31.00 to $210.00. On average, they anticipate CRISPR Therapeutics' share price to reach $147.67 in the next year. This suggests a possible upside of 17.5% from the stock's current price.
View analysts' price targets for CRISPR Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are CRISPR Therapeutics' key executives?

CRISPR Therapeutics' management team includes the following people:
  • Dr. Rodger Novak, Founder, Chairman & Pres (Age 54)
  • Dr. Samarth Kulkarni, CEO & Director (Age 42, Pay $994.55k)
  • Mr. Michael John Tomsicek, Chief Financial Officer (Age 55, Pay $632.72k)
  • Dr. Lawrence Otto Klein Ph.D., Chief Operating Officer (Age 38, Pay $579.23k)
  • Mr. James R Kasinger, Gen. Counsel & Sec. (Age 49, Pay $605.3k)
  • Dr. Tony W. Ho M.D., Exec. VP of R&D (Age 55, Pay $722.98k)
  • Mr. Shaun Foy, Founder
  • Dr. Emmanuelle Marie Charpentier, Co-Founder & Scientific Advisory Board Member
  • Dr. Craig C. Mello, Scientific Founder & Advisory Board Member
  • Dr. Chad Cowan, Scientific Founder

Who are some of CRISPR Therapeutics' key competitors?

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Square (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an IPO on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Nikko Asset Management Americas Inc. (5.39%), Price T Rowe Associates Inc. MD (2.49%), BlackRock Inc. (1.65%), Morgan Stanley (1.03%), Federated Hermes Inc. (0.89%) and Wells Fargo & Company MN (0.65%). Company insiders that own CRISPR Therapeutics stock include Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Pablo J Cagnoni, Rodger Novak, Samarth Kulkarni and Tony W Ho.
View institutional ownership trends for CRISPR Therapeutics

Which major investors are selling CRISPR Therapeutics stock?

CRSP stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Bank of New York Mellon Corp, Orbimed Advisors LLC, Armistice Capital LLC, Federated Hermes Inc., Clough Capital Partners L P, Wells Fargo & Company MN, and Columbus Circle Investors. Company insiders that have sold CRISPR Therapeutics company stock in the last year include Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, and Tony W Ho.
View insider buying and selling activity for CRISPR Therapeutics
or view top insider-selling stocks.

Which major investors are buying CRISPR Therapeutics stock?

CRSP stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Price T Rowe Associates Inc. MD, Nikko Asset Management Americas Inc., Hitchwood Capital Management LP, FIL Ltd, WBI Investments, JPMorgan Chase & Co., and Nia Impact Advisors LLC.
View insider buying and selling activity for CRISPR Therapeutics
or or view top insider-buying stocks.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $125.69.

How much money does CRISPR Therapeutics make?

CRISPR Therapeutics has a market capitalization of $9.48 billion and generates $289.59 million in revenue each year. The company earns $66.86 million in net income (profit) each year or $1.17 on an earnings per share basis.

How many employees does CRISPR Therapeutics have?

CRISPR Therapeutics employs 304 workers across the globe.

What is CRISPR Therapeutics' official website?

The official website for CRISPR Therapeutics is www.crisprtx.com.

Where are CRISPR Therapeutics' headquarters?

CRISPR Therapeutics is headquartered at BAARERSTRASSE 14, ZUG V8, CH-6300.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at 41-41-561-3277 or via email at [email protected]

This page was last updated on 2/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.